Cargando…
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody-Drug Conjugates (ADCs) are a class of cancer therapeutics that combines antigen specificity and potent cytotoxicity in a single molecule as they are comprised of an engineered antibody linked chemically to a cytotoxic drug. Four ADCs have received approval by the Food and Drug Administratio...
Autores principales: | Chalouni, Cécile, Doll, Sophia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802061/ https://www.ncbi.nlm.nih.gov/pubmed/29409507 http://dx.doi.org/10.1186/s13046-017-0667-1 |
Ejemplares similares
-
Antibody Drug Conjugate Bioinformatics: Drug Delivery through the Letterbox
por: Vlachakis, Dimitrios, et al.
Publicado: (2013) -
Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018) -
Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016) -
Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020) -
Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)